## TB Alliance R&D Partners:

**Discovery**

- ATP Synthesis Inhibitors: Calibr
- Whole-Cell Hit-to-Lead Program: Sanofi

**Lead Identification**

- Whole-Cell Hit-to-Lead Program: GSK
- RNA Polymerase Inhibitors: Rutgers University
- Energy Metabolism Inhibitors: AZ/UPenn

**Lead Optimization**

- POA Prodrugs: Yonsei
- InhA Inhibitors
- Hit ID Program: Takeda
- Hit ID Program: Daiichi Sankyo
- Hit ID Program: Shionogi

**Preclinical Development**

- Diarylquinolines: Janssen/University of Auckland/UIC
- Indazoles: GSK
- Thiophene Carboxamides: Calibr

**Phase 1**

- DprE1 Inhibitors
- Cyclopeptides: Sanofi
- Mmp13 Inhibitors
- Oxazolidinones: IMM
- Pyrimidines: GSK

**Phase 2A**

- Preclinical TB Regimen Development: JHU
- Pharmacokinetics of first-line drugs in children < 5kg: Stellenbosch University

**Phase 2B**

- Pretomanid/Bedaquiline/Pyrazinamide (BPAZ)

**Phase 3**

- NC-005
- STAND: Pretomanid/Moxifloxacin/Pyrazinamide (PaMZ)

## Late Development

**Optimized Pediatric Formulations**

- Ethambutol/Rifampicin/Pyrazinamide for children > 5kg
- Isoniazid/Rifampicin for children > 5kg
- Ethambutol for children > 5kg
- Isoniazid for children > 5kg
- Pyrazinamide for children > 5kg

**Early Development**

- Macrolides: Sanofi
- Ureas: Sanofi

**Discovery**

- Pretomanid
- Moxifloxacin
- Pyrazinamide

**Preclinical TB Regimen Development**

- Early Development

**Rutgers University**

**Shionogi**

**Medical Research Council (MRC) at UCL**

**Daiichi Sankyo**

**GlaxoSmithKline (GSK)**

**Institute of Materia Medica (IMM)**

**Janssen [Johnson & Johnson]**

**Johns Hopkins University (JHU)**

**Medical Research Council (MRC) at UCL**

**OP-BIO**

**Roche Pharmaceuticals**

**Sanofi**

**Schrodinger**

**Shionogi**

**Stellenbosch University**

**Takeda Pharmaceuticals**

**TB Drug Accelerator (TBDA)**

**University College London (UCL)**

**University of Auckland**

**University of Illinois at Chicago (UIC)**

**University of Pennsylvania School of Medicine (UPenn)**

**Yonsei University**